APA (7th ed.) Citation

Oberg, D., Yanover, E., Adam, V., Sweeney, K., Costas, C., Lemoine, N. R., & Halldén, G. (2010). Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clinical cancer research, 16(2), 541. https://doi.org/10.1158/1078-0432.CCR-09-1960

Chicago Style (17th ed.) Citation

Oberg, Daniel, Eva Yanover, Virginie Adam, Katrina Sweeney, Celina Costas, Nick R. Lemoine, and Gunnel Halldén. "Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers." Clinical Cancer Research 16, no. 2 (2010): 541. https://doi.org/10.1158/1078-0432.CCR-09-1960.

MLA (9th ed.) Citation

Oberg, Daniel, et al. "Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers." Clinical Cancer Research, vol. 16, no. 2, 2010, p. 541, https://doi.org/10.1158/1078-0432.CCR-09-1960.